Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Jeff P Sharman; Miklos Egyed; Wojciech Jurczak; Alan Skarbnik; John M Pagel; Ian W Flinn; Manali Kamdar; Talha Munir; Renata Walewska; Gillian Corbett; Laura Maria Fogliatto; Yair Herishanu; Versha Banerji; Steven Coutre; George Follows; Patricia Walker; Karin Karlsson; Paolo Ghia; Ann Janssens; Florence Cymbalista; Jennifer A Woyach; Emmanuelle Ferrant; William G Wierda; Veerendra Munugalavadla; Ting Yu; Min Hui Wang; John C Byrd

doi:10.1038/s41375-021-01485-x

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Leukemia. 2022 Apr;36(4):1171-1175. doi: 10.1038/s41375-021-01485-x. Epub 2022 Jan 1.

Authors

Jeff P Sharman¹, Miklos Egyed², Wojciech Jurczak³, Alan Skarbnik⁴, John M Pagel⁵, Ian W Flinn⁶, Manali Kamdar⁷, Talha Munir⁸, Renata Walewska⁹, Gillian Corbett¹⁰, Laura Maria Fogliatto¹¹, Yair Herishanu¹², Versha Banerji¹³, Steven Coutre¹⁴, George Follows¹⁵, Patricia Walker¹⁶, Karin Karlsson¹⁷, Paolo Ghia¹⁸, Ann Janssens¹⁹, Florence Cymbalista²⁰, Jennifer A Woyach²¹, Emmanuelle Ferrant²², William G Wierda²³, Veerendra Munugalavadla²⁴, Ting Yu²⁴, Min Hui Wang²⁴, John C Byrd²¹

Affiliations

¹ Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA. Jeff.Sharman@USONCOLOGY.COM.
² Somogy County Mór Kaposi General Hospital, Kaposvár, Hungary.
³ Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland.
⁴ Novant Health Cancer Institute, Charlotte, NC, USA.
⁵ Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USA.
⁶ Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA.
⁷ University of Colorado Cancer Center, Aurora, CO, USA.
⁸ Haematology, Haematological Malignancy Diagnostic Service (HMDS), St. James's Institute of Oncology, Leeds, UK.
⁹ Cancer Care, University Hospitals Dorset, Bournemouth, UK.
¹⁰ Tauranga Hospital, Tauranga, New Zealand.
¹¹ Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.
¹² Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
¹³ Departments of Internal Medicine, Biochemistry & Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba and CancerCare Manitoba Research Institute, Winnipeg, MB, Canada.
¹⁴ Stanford University School of Medicine, Stanford, CA, USA.
¹⁵ Department of Haematology, Addenbrooke's Hospital NHS Trust, Cambridge, UK.
¹⁶ Peninsula Health and Peninsula Private Hospital, Frankston, Melbourne, VIC, Australia.
¹⁷ Skåne University Hospital, Lund, Sweden.
¹⁸ Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy.
¹⁹ University Hospitals Leuven, Leuven, Belgium.
²⁰ Bobigny: Hématologie, CHU Avicennes, Bobigny, France.
²¹ The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
²² Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie Clinique, Pierre-Bénite, France.
²³ Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.
²⁴ AstraZeneca, South San Francisco, CA, USA.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Benzamides
Chlorambucil / therapeutic use
Follow-Up Studies
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Pyrazines

Substances

Antibodies, Monoclonal, Humanized
Benzamides
Pyrazines
Chlorambucil
acalabrutinib
obinutuzumab